Quarterly guidance

Adjusted EPS
$1.62 to $1.67 for the fourth quarter.
Foreign exchange impact
Negative impact of approximately 1% on fourth quarter sales.

Annual guidance

Annual guidance
No specific annual guidance was provided for 2027, though management expects sales growth to accelerate.

Outlook

Nutrition spin-off
Expected to be completed by the end of next year, with the new company qualifying for the S&P 500.
Diabetes market
Growth expected in the low to mid-single range for the next few quarters due to pricing pressure and lack of reimbursement expansion.
Electrophysiology
Expects to reignite growth and capture share with the launch of the Amulet 360 and other new products.
R&D investment
R&D spending is increasing to over $3 billion this year and will continue to increase into next year.
Capital allocation
The company plans to maintain a balanced approach, including dividend growth and potential tuck-in M&A.
2027 outlook
Management expects total company growth to accelerate in 2027 compared to 2026.